PORPHYRIN DIMER PDT · Porphyrin dimers for photodynamic therapy via two photon absorption
6РП — Действия „Мария Кюри“
- Период
- 2006-11-01 → 2008-07-31
- Финансиране от ЕС
- 159 613 €
- Участници
- 1
- Схема
- EIF
Линиите свързват координатора с партньорите.
Накратко на български
Порфириновите димери са нови съединения, които стават токсични само при облъчване с два фотона едновременно, което позволява прецизно затваряне на кръвоносни съдове. Методът подобрява селективността на фотодинамичната терапия и намалява увреждането на здравите тъкани при лечение на макуларен дегенерация и неврохирургични операции.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
Final Activity Report Summary - PORPHYRIN DIMER PDT (Porphyrin Dimers for Photodynamic Therapy via Two Photon Absorption)
We designed and successfully synthesised a series of water soluble conjugated porphyrin dimers. We fully explored their photophysical and biological properties and showed that all synthesised dimers had very high two-photon absorption cross-sections, i.e. very high ability to absorb two photons simultaneously, and singlet oxygen yields, properties crucial for practical applications of two-photon photodynamic therapy. Porphyrin dimers are a new class of compounds that become toxic only when struck by two photons simultaneously. This means that very few cells outside of the most intense part of the laser focus are affected. Importantly, low-energy near-infrared light can be used, which can penetrate two or three times deeper into living tissue than the currently common laser. This property should allow for broader application for photodynamic therapy (PDT) in medicine. Using these conjugated porphyrin dimers we were able to demonstrate, for the first time, blood vessel closure in a live mammal by highly selective two-photon excited PDT. Our research outlined a novel method which increased the selectivity of photodynamic therapy and minimised collateral damage. The most immediate application was the treatment of the wet form of age-related macular degeneration (AMD) by closing off unwanted blood capillaries. Other possible applications emerged particularly in neurosurgery, where precise minimally-invasive treatment is of key importance. Our research article describing the above results was highlighted in Nature, entitled Cancer zapper, as well as in Chemistry World, entitled Improving photodynamic cancer therapy.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
Conjugated porphyrin dimers are promising chromophores for photodynamic therapy (PDT) because of their strong two-photon absorption at wavelengths around 850 nm, as well as their strong one-photon absorption between 650-750 nm. PDT via two-photon absorption, using a pulsed Ti-sapphire laser, should be an effective method for treating age-related macular degeneration (AMD) which is a common cause for blindness.The advantage of two-photon excitation is that it minimises collateral damage. These chromophores may also lead to promising one-photon PDT sensitisers because they absorb at wavelengths where there is minimal absorption or scattering by living tissues. We already know that conjugated porphyrin dimers possess the necessary photophysical characteristics for PDT as they have high singlet oxygen yields (singlet oxygen is the primary cytotoxic species formed during PDT).The challenge now is to synthesize biocompatible porphyrin dimers and learn how to deliver them into living cells and how to control their sub-cellular localization. The project will address these issues by exploring a range of molecular architectures and drug delivery techniques. Dr. Balaz is a very talented young researcher in the field of organic synthesis, physical organic chemistry, and spectroscopy.The proposed project presents a well balanced combination of fundamental and applied research on the intersection of organic synthesis, photophysics and biological chemistry. Completion of this interdisciplinary project would allow him to share his expertise with his colleagues from Slovakia, where he could introduce new research frontiers.The project addresses one of the major thematic priorities of the European Union's Sixth FrameWork Programme: Life sciences, Genomics and Biotechnology for Health. It explores the highly important area of preparation of new, more effective drugs and offers new approaches which are more elegant and less invasive in combating diseases.
Оригинален текст от CORDIS (на английски).
Участници
- THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD · OXFORDКоординаторОбединеното кралство
Връзки
Данни: CORDIS, © Европейски съюз